Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

在国家自然科学基金项目（批准号：82072784、82072785、82273304、82303437）等资助下，复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...

The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...

In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase ...

China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...